5 Top Gainers In Healthcare Sector (LCI, SOLY, EVOK...)

(RTTNews) - The following are some of today's top gainers in the healthcare sector.

1. Lannett Company Inc. (LCI)

Lannett Company markets and distributes generic pharmaceutical products for a wide range of medical indications.

Gained 40.80% to close Monday's (July 22) trading at $8.42.

News: No news

Near-term Catalyst:

The Company is slated to report financial results for fiscal 2019 fourth quarter and full year ended June 30, 2019, in the last week of August.

For fiscal 2019, the Company expects annual net sales to be in the range of $640 million to $645 million. Net sales reported in fiscal 2018 were $684.6 million.

2. Soliton Inc. (SOLY)

Soliton is a medical device company, which recently received FDA clearance to market its Rapid Acoustic Pulse ("RAP") device for tattoo removal. The potential of the RAP device is also being explored to reduce cellulite and enhance existing fat removal technologies.

Gained 21.85% to close Monday's trading at $14.72.

News: No news

Recent events:

-- On July 16, 2019, the Company submitted its pivotal cellulite clinical trial protocol for independent Institutional Review Board approval. -- On May 29, 2019, the Company announced positive results from its proof-of-concept trial of a new higher-powered version of Rapid Acoustic Pulse (RAP) device, with 20-47% improvement in cellulite severity score. This new higher-powered version of RAP device is not yet approved by the FDA.

3. Achillion Pharmaceuticals Inc. (ACHN)

Achillion Pharma is a clinical-stage biopharmaceutical company developing orally-administered, small molecule, Factor D inhibitors for the treatment of Paroxysmal Nocturnal Hemoglobinuria, C3 Glomerulopathy and immune complex membranoproliferative glomerulonephritis.

Gained 16.39% to close Monday's trading at $2.77.

News: The Company announced positive results from its Phase 1 multiple ascending dose (MAD) study with ACH-5228 in healthy volunteers outside of the United States. ACH-5228 is expected to move into phase II clinical trials in multiple diseases.

Near-term Catalyst:

The Company expects to submit an IND application to the U.S. FDA supporting clinical development for ACH-5228 in the fourth quarter of 2019.

4. Acasti Pharma Inc. (ACST)

Acasti is focused on the research, development, and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia (HTG).

Gained 14.62% to close Monday's trading at $1.96.

News: No news

Clinical Trials and Near-term Catalysts:

-- The Company's lead product candidate CaPre for the treatment of severe hypertriglyceridemia is under two phase III trials, dubbed TRILOGY 1 and TRILOGY 2. The topline results for the primary endpoint of lowering triglycerides for TRILOGY 1 are expected in December 2019 and for TRILOGY 2 in January 2020.

5. Evoke Pharma Inc. (EVOK)

Evoke Pharma is a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases.

Gained 12.84% to close Monday's trading at $1.23.

News: No news

Recent event:

-- On June 27, 2019, the Company announced that it has submitted a type A meeting request and meeting package to the FDA to discuss the Complete Response Letter issued on April 1, 2019, for Gimoti.

The Company is developing Gimoti for the relief of symptoms associated with acute and recurrent diabetic gastroparesis.

The type A meeting, if granted, is expected to occur within thirty days of FDA's receipt of the meeting request and meeting package, i.e., by the end of this month.